Diabetology & metabolic syndrome

Ecnoglutide's safety and treatment effects for type 2 diabetes: a review and combined analysis

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Ecnoglutide is a novel cAMP-biased GLP-1 receptor agonist that may improve glycemic control and promote weight loss in individuals with Type 2 diabetes mellitus.

  • Type 2 diabetes mellitus is increasingly recognized as a significant global health issue.
  • Effective therapies are needed to enhance glycemic control and support weight loss.
  • Ecnoglutide has potential as a new treatment option for managing this condition.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
2 weeks ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
3 weeks ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
4 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
5 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
6 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
7 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
8 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
9 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
10 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
11 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief